Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 18Prostate Adenocarcinoma 2Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1PSA Level Greater Than Two 1Granulosa cell tumor of the ovary 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cisplatin 4Carboplatin 4Biopsy 4trastuzumab deruxtecan 3Trastuzumab 3Platinum 3Goserelin 3Docetaxel 3sacituzumab govitecan 2pertuzumab 2entrectinib 2darolutamide 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1spartalizumab 1selinexor 1pyrotinib 1luprolide acetate gel depot 1lenvatinib 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × luprolide acetate gel depot × 1 year × Clear all
NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡